Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.35
- Piotroski Score 4.00
- Grade Neutral
- Symbol (RCUS)
- Company Arcus Biosciences, Inc.
- Price $14.82
- Changes Percentage (3.78%)
- Change $0.54
- Day Low $14.20
- Day High $15.07
- Year High $20.31
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $32.00
- High Stock Price Target $46.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.11
- Trailing P/E Ratio -4.98
- Forward P/E Ratio -4.98
- P/E Growth -4.98
- Net Income $-307,000,000
Income Statement
Quarterly
Annual
Latest News of RCUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ben Middlebrooks, Marcus Hill guide NC State to 72-49 romp over Colgate
NC State's Middlebrooks and Hill led the team to a 72-49 win over Colgate. Middlebrooks scored 19 points and Hill added 17. The Wolfpack dominated the game with a strong performance and balanced scori...
By AP NEWS | 3 days ago -
Opinion: Mike Tyson vs. Jake Paul fight represents the circus that is America
Days before their Netflix fight, Mike Tyson and Jake Paul defend their bout as culturally relevant. The event symbolizes a society driven by spectacle and social media influence, challenging tradition...
By USA Today | 1 week ago -
Big Apple Circus Review: A City Tour, Pizza Rats Included
The Big Apple Circus at Lincoln Center featured acts like poodles, acrobats, and clowns in its Hometown Playground theme. Despite some mishaps, the show provided a nostalgic and entertaining escape fo...
By The New York Times | 1 week ago
